Monash University researchers conducted a new study that showed that “nitroxyl”, the chemical compound, could be an effective and quick intervention for cardiovascular emergencies in type II diabetes mellitus (T2DM).
Although Nitroxyl was recently recognized as a potential pharmacological treatment for heart failure, it is the first time that it has been shown to be an intervention for T2DM.
The Monash Institute of Pharmaceutical Scientists published the study. British Journal of PharmacologyThe following article highlights the therapeutic benefits of nitroxyl for cardiovascular emergencies like acute ischemia and heart failure. This is where the blood supply to tissues decreases, leading to a reduction or oxygen supply to the affected areas.
Researchers set out to determine if T2DM promotes resistance to nitric oxide in the heart and vascular systems and if tissue responsiveness is affected by nitroxyl.
The team published the initial report on T2DM in animal models. It is the first to show that T2DM can actually cause nitric dioxide resistance in the coronary arteries and mesenteric vessels. This resistance is then overcome by Angeli’s salt, a nitroxyl donors.
This is due to the rapid growth of T2DM, an epidemic that affects over 463 million people around the world. It is predicted that this number will rise to 700 million by 2045.
T2DM patients have a greater risk of developing symptomatic cardiac failure. This condition has a poor prognosis and a 5-year mortality rate of 75%.
Anida Velagic, a MIPS Drug Discovery Biology Ph.D. candidate, and the first author of the study said that patients with T2DM have a higher risk of dying from cardiovascular events, and that there is an urgent demand for a therapy that is not nitric oxide.
“Nitric oxide plays a vital role in maintaining cardiovascular well-being.” Ms. Velagic said that patients with diabetes and acute coronary syndromes are more likely to develop resistance to nitric dioxide. This can lead to a worsening of their long-term prognosis, as well as an increase in the risk of cardiovascular events such heart attack or stroke.
“This is why we need another therapy to circumvent this problem. This study has provided the first evidence that Angeli’s salt, a nitroxyl donor, can overcome nitric oxide resistance in mesenteric and coronary vasculature.
Professor Rebecca Ritchie is the leader of MIPS’ Drug Discovery Biology Theme and senior author on the study. She said that the findings were a great development in the team’s ongoing search for new therapeutic strategies that can prevent, delay, or stop the progression of cardiovascular disease.
Professor Ritchie said, “Our research at MIPS focuses around the identification and implementation of new strategies to arrest the progression of heart failure, especially in the contexts of diabetes.”
The study, entitled “Cardioprotective effects of nitroxyl donors Angeli’s sodium are preserved in diabetic heart and vasculature under nitric oxide resistance,” was published by the British Journal of Pharmacology.
Children’s recovery from heart surgery is not improved by nitric oxide
Anida Velagic and colleagues, Cardioprotective actions from nitroxyl donor Angeli’s salt are preserved by the diabetic heart, vasculature, and face to nitric oxide resistance British Journal of Pharmacology (2022). DOI: 10.1111/bph.15849
The promising therapeutic intervention of Nitroxyl for type 2 diabetes-related cardiovascular emergencies (2022, August 16).
Retrieved 16 August 2022
This document is subject of copyright. Except for any fair dealings in private study or research, this document is not subject to copyright.
Part may not be reproduced without written permission. This content is only for informational purposes.
Source: medical xpress.